Rituximab, Cyclophosphamide, Bortezomib and Prednisone (R-CBorP): Final Results of a Phase I Trial Evaluating Two Dosing Schedules and the Safety of Overlapping Pegfilgrastim in Patients with Relapsed/Refractory Indolent and Mantle Cell Lymphomas.
| Autor: | Gerecitano, John, Portlock, Carol S., Hamlin, Paul A., Jr., Moskowitz, Craig H, Noy, Ariela, Straus, David J., Schulman, Philip, Dumitrescu, Otilia *, Sarasohn, Debra *, Pappanicholaou, Jennifer *, Iassonos, Alexia *, Zhang, Zhigang *, Horanlli, Endri *, Rojas, Celeste N *, Zelenetz, Andrew D. *, O'Connor, Owen A * |
|---|---|
| Zdroj: | In Blood 20 November 2009 114(22):3708-3708 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|